🔗 Share this article

While the US undertakes sweeping revisions to its immunization schedules, a particular individual has emerged in a surprising turn: Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by casting doubt on Covid vaccinations in the global health crisis and has zeroed in on possible fatalities after COVID-19 immunization in her short position at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Program

Public health authorities had intended to unveil major revisions to the childhood immunization program earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a major change that would put the US out of step with much of the global community with little proof for improved outcomes. The planned update has been postponed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is set to present at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to head the division this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics divisions as Høeg and Prasad consolidate power at the FDA – and it points to a renewed priority upon rolling back previously authorized immunizations at the FDA.

The new acting director has often pushed for discontinuing certain pediatric vaccine recommendations in the US so as to align more similar to Denmark, a society with comprehensive healthcare and a number of inhabitants about the population of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccination policy – typically the purview of Dr. Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Expertise

Dr. Høeg has little discernible experience in drug development, oversight or management, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for leading the CDER, stated Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in managing a sizeable institution. She has no expertise in drug approvals.”

Past directors of the center would “grasp legal statutes and the research of drug development”, noted Janet Woodcock. “Frankly, she has not acquired the sort of resume that previous people who led the center have had.”

CDER has an enormous workload at the agency, she emphasized.

“The public just focuses on the new drug program, but the generic program authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and other areas, and every single one must be supervised,” she noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a significant management aspect to the position, which manages in excess of 5,000 personnel. “It is a massive management job, if you perform it correctly,” Woodcock said.

Agency Reaction and Controversial Policies

When asked about inquiries about Dr. Høeg's credentials and whether this assignment indicates greater collaboration among regulatory chiefs on vaccines, a spokesperson responded that the “inquiries are based on incorrect presumptions”.

“Her resume matches the duties of her position,” the official stated, noting the months Høeg spent counseling the agency head on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg takes over the commissioner’s new fast-track approval initiative, a contentious rapid therapy clearance system that apparently troubled her preceding directors. “By what process are these therapies being picked for this fast-track system? Who is making the decisions?” Dr. Howard said. “There’s a lot of lack of transparency happening at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards less stringent rules of most medications, with the exception of shots.”

Public Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if troubling, history, Howard have noted. She released a research paper using unverified public submissions to estimate the rate of heart inflammation following Covid immunization. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the incoming government included revising rules for recently developed shots and halting “non-essential” vaccines, she remarked after the election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of excluding young men from receiving COVID-19 vaccinations.

“She’s an complete true believer who starts off with her beliefs and reverse-engineers to accommodate the data in a highly disingenuous, untruthful way,” Dr. Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with fellow skeptics, {like|